GDNF and Parkinson disease: They describe clinical improvement in MPTP-lesioned PD monkeys, as well as indications of functional recovery in the nigrostriatal pathway, without any major adverse effects and persistent GDNF expression over a period of 12 months (Albert et al., 2017; Grondin et al., 2019).